These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19524334)

  • 1. [Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].
    Lidove O; Papo T
    Rev Med Interne; 2009 Oct; 30(10):920-9. PubMed ID: 19524334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature.
    Lidove O; Joly D; Barbey F; Bekri S; Alexandra JF; Peigne V; Jaussaud R; Papo T
    Int J Clin Pract; 2007 Feb; 61(2):293-302. PubMed ID: 17263716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
    Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.
    Lidove O; West ML; Pintos-Morell G; Reisin R; Nicholls K; Figuera LE; Parini R; Carvalho LR; Kampmann C; Pastores GM; Mehta A
    Genet Med; 2010 Nov; 12(11):668-79. PubMed ID: 20962662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.
    Spada M; Baron R; Elliott PM; Falissard B; Hilz MJ; Monserrat L; Tøndel C; Tylki-Szymańska A; Wanner C; Germain DP
    Mol Genet Metab; 2019 Mar; 126(3):212-223. PubMed ID: 29785937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
    Senocak Tasci E; Bicik Z
    Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The switch of enzyme therapy in Fabry disease].
    Riccio E; Pisani A
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on role of agalsidase alfa in management of Fabry disease.
    Ramaswami U
    Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
    Kizhner T; Azulay Y; Hainrichson M; Tekoah Y; Arvatz G; Shulman A; Ruderfer I; Aviezer D; Shaaltiel Y
    Mol Genet Metab; 2015 Feb; 114(2):259-67. PubMed ID: 25155442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.
    Pisani A; Visciano B; Roux GD; Sabbatini M; Porto C; Parenti G; Imbriaco M
    Mol Genet Metab; 2012 Nov; 107(3):267-75. PubMed ID: 22963910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
    Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
    Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
    J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.